Brought to you by 
Intercept nets $367mm in second FOPO in as many months
07 Apr 2015
Executive Summary
In its second follow-on offering in just as many months, Intercept Pharmaceuticals Inc. (focused on hepatic diseases; also developing in Type II diabetes and fibrosis) netted $367mm by selling 1.3mm shares (including partial exercise of the overallotment) for $276.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intercept nets $367mm in second FOPO in as many months
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice